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vs. 4.6 ± 8.9; P = 0.0029) and interventions (5.8 ± 11.1 vs. 0.7 ± 1.1; P = 0.0042). 
Only 11.6% of PD patients used an ambulance or transport organized by the dialysis 
center/sickness fund, compared with 67.8% for HD. The estimated annual cost for 
the public payer (PP) was c72,350 per HD and c55,343 per PD patient (i.e., 31% 
more). As in 2006 there were approximately 6400 patients on dialysis (90% on HD, 
10% on PD), the PP total cost is estimated to be around c452 million (2.45% of 2006 
health care budget). The dialysis procedure was the main cost driver (66% of costs) 
being 27% more expensive for HD. Hospital and ambulatory services were respec-
tively 28% and 45% more expensive for HD. CONCLUSIONS: The economic burden 
of dialysis is important in Belgium. Considering that survival of PD patients is at least 
as good as that of HD patients and that home-treatment reduces exposure to hospital 
pathogens, PD represents good value for money and should be considered in more 
patients.
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OBJECTIVES: A patient suffering from end stage renal disease (ESRD) has two treat-
ment options, lifelong dialysis or renal transplantation. The aim of this review is to 
determine economic cost of illness associated with renal transplantation and dialysis 
in ESRD in the United States (US). METHODS: The information was retrieved from 
databases including Medline, EMBASE, United States Renal Data System (USRDS), 
WHO and relevant grey literature. Studies reporting data for cost associated with 
transplantation and dialysis in ESRD in the US were included. RESULTS: In 2007, 
hemodialysis (HD) was initiated in 99,886 patients, peritoneal dialysis (PD) in 6376 
patients and transplantation in 2500 patients in the US. Total Medicare costs associ-
ated with these were $17.6 billion for HD, $949 million for PD and $1.9 billion for 
transplantation (USRDS 2009). Unadjusted average annual Medicare expenditure 
(2004 US$) for PD and HD as ﬁ rst modalities was $53,277 and $72,189 respectively 
(Shih 2005). Patients with HD were twice as likely to be hospitalised over a 12-month 
period compared to matched PD patients. The median health care costs associated 
with hospitalization were $173,507 for HD patients vs. $129,997 for PD patients 
(Berger 2009). The mean length of stay was signiﬁ cantly less for PD with 6.57 days 
(P < 0.0001) vs. 7.25 days for HD (Walker 2009). The mean cost of treating S. aureus 
bacteraemia in HD patients, including readmissions and outpatient costs, was $24,034 
per episode (Engemann 2005). Over a 25 year time horizon, renal transplantation 
resulted in signiﬁ cant cost savings with a cost of $376,577/patient and life expectancy 
of 7.4 years compared to $568,670/patient and life expectancy of 6.7 years with long 
term dialysis (Quinn 2007). CONCLUSIONS: Renal transplantation results in signiﬁ -
cant cost savings compared to long term dialysis. The total health care costs associated 
with hemodialysis are higher compared to peritoneal dialysis.
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OBJECTIVES: This analysis was done to assess if co-morbidities inﬂ uence the public 
payer (PP) cost of dialysis patients in Belgium. METHODS: The data from a cost 
study (retrospective chart review of 130 Belgian patients undergoing dialysis in 2006) 
was analyzed a posteriori. Baseline medical characteristics were used to compute the 
Charlson co-morbidity score (CCMS). Costs included: dialysis procedure and medical 
management (i.e., hospitalizations, outpatient visits and procedures, laboratory and 
imaging tests, and transport). Multivariate analyses were performed with the logarith-
mic transformation of costs as the dependent variable and CCMS, dialysis modality 
(hemodialysis: HD or peritoneal dialysis: PD) and gender as the independent variables. 
The regression model was weighted by number of patient months in the study. CCMS 
was categorized as low (<4), moderate (4–5), high (6–7) and very high (> = 8). 
RESULTS: All 3 variables had a signiﬁ cant impact on costs. Total costs to the PP were 
16% higher for HD than for PD patients (p = 0.0039) and were 13% higher in women 
than in men (p = 0.0207). The costs in patients with a very high CCMS were 21% 
higher than those with a low or moderate score (p = 0.0072 and p = 0.0094 respec-
tively) and 10.7% higher than those with a high score, but this latter difference did 
not reach statistical signiﬁ cance (p = 0.1160). The differences were larger when exclud-
ing the cost of dialysis procedure and considering medical management only, but only 
reached statistical signiﬁ cance or patients having a very high CCMS score vs. low or 
moderate CCMS (p = 0.0036 and 0.0056 respectively). CONCLUSIONS: This analy-
sis showed that patient co-morbidities have a signiﬁ cant impact on medical manage-
ment and total costs of dialysis patients. It is therefore important to take this into 
consideration when studying the costs of dialysis patients, especially if a total cost 
approach (i.e., procedure plus medical management) is taken.
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OBJECTIVES: Complications due to late dialysis referral after graft loss involve higher 
medical costs, together with a worsened health status and higher mortality rates. The 
efﬁ ciency of timely (TDR) versus late dialysis referral (LDR) after renal transplant failure 
is evaluated for the Spanish case. METHODS: A Markov model was developed and 6 
health states were deﬁ ned: hemodialysis (HD), peritoneal dialysis (PD), transplant (TX), 
late referral hemodialysis (LRHD), late referral peritoneal dialysis (LRPD) and death 
(D). a hypothetical cohort of patients aged 45 was observed during 40 years, considering 
age-dependent mortality rates. Transition probabilities were estimated using data from 
the Spanish Nephrology Society registry. Costs (in 2009 EUR) were obtained from a 
comprehensive literature review and included both direct (DC) (medical and non-
medical) and indirect costs (IC) (lost labor productivity due to mortality and morbidity). 
Effectiveness was measured in terms of Quality Adjusted Life-years (QALYs). Health 
utilities were estimated from a proprietary database. a discount rate of 3.5% was 
considered for both cost and effectiveness ﬁ gures. All the model parameters were sup-
ported by an expert panel. Incremental Cost-Effectiveness Ratios (ICERs) and Net 
Health Beneﬁ ts (NHBs) were computed. a willingness-to-pay threshold of c35,000/
QALY was taken into account. Both univariate and Monte Carlo multivariate sensitivity 
analyses were performed. RESULTS: The ICER was c27,385/QALY (IC not included) 
and c34,051/QALY [IC included], providing NHBs of (0.08) [0.01]. TDR yielded 0.37 
additional QALY/patient. The multivariate sensitivity analysis showed that TDR was 
efﬁ cient in (54%) [53%] and dominant in (28%) [27%] of the simulations. The prob-
ability of accepting TDR was (55%) [50%]. CONCLUSIONS: TDR is an efﬁ cient 
scenario when compared to LDR, providing a greater number of QALYs with yet an 
affordable increase in costs. Our results, however, raise the debate on the suitability of 
the willingness-to-pay threshold as a rigid decision tool.
PUK19
ECONOMIC EVALUATION OF ALISKIREN IN TYPE 2 DIABETES AND 
HYPERTENSION PATIENTS WITH NEPHROPATHY IN MEXICO
Nevarez A1, García-Contreras F1, Olvera K2
1Mexican Institute of Social Security, Mexico City, D.F., Mexico; 2Novartis, Mexico City, D.F., 
Mexico
OBJECTIVES: To determine the most cost-effective alternative between a) Losartan, 
and b) Losartan + Aliskiren in type 2 diabetes and hypertension patients with micro-
albuminuria in the Mexican Institute of Social Security. METHODS: A complete 
economic evaluation was performed from institutional perspective, using a Markov 
model as analytical tool with semi-annual cycles and follow up until death, with 
transversal analyses at 10, 15 and 20 years. Simulating a cohort with a 53 years old 
patient with type 2 diabetes, hypertension, and microalbuminuria and using a dis-
counting rate of 5% in costs and effectiveness. One assumption is that all patients 
that require dialysis receive it. Proportion of patients who have not received dialysis, 
as well as survival and quality of life were considered as effectiveness end points. 
Transition probabilities were obtained from AVOID study and IMSS information. 
Resource use was obtained from IMSS data and costs are considered in 2009 USD. 
Probabilistic and non-probabilistic sensitivity analysis was performed. RESULTS: 
Keeping a patient in stages prior to dialysis at 20 years of follow-up requires an 
investment of $19,647 with Losartan and $18,774 with Losartan + Aliskiren. After 
14 years of follow up, Aliskiren + Losartan is dominant versus the use of Losartan. 
CONCLUSIONS: Aliskiren + Losartan is a cost-saving alternative if administered for 
prolonged periods, being the most effective regardless the period of monitoring and 
effectiveness measurement used.
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OBJECTIVES: To assess the cost-effectiveness between two non-calcium binders, 
lanthanum carbonate (LC) and sevelamer hydrochloride (SH), in end-stage renal 
disease (ESRD) patients previously treated with calcium-based binders. METHODS: 
A Markov model was developed to estimate incremental costs for three health out-
comes: 1) quality-adjusted life-years (QALYs), 2) Life-years saved (LYS) and 3) percent 
who successfully met serum phosphorus (SP) level goals (3.5–5.5 mg/dl) between the 
two non-Ca binders. The model incorporated patient-level data from a randomized 
head-to-head crossover study which compared the reduction of SP using ﬁ xed doses 
of LC for 4 weeks. For this analysis the model included patients previously treated 
with calcium-based binders. The ‘intent-to-treat’ (ITT) population and the ‘completer’ 
population were assessed. Baseline risks of cardiovascular disease (CVD), overall 
mortality, and CVD mortality were derived from a large US epidemiological study. 
Utilities, costs and relative risks of CVD were derived from published sources. Patient 
outcomes were modeled for 10 years, and incremental cost-effective ratios (ICERs) 
were calculated for LC relative to SH. Clinical and economic outcomes were dis-
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counted at 5% per year. Deterministic and probabilistic sensitivity analyses (PSA) were 
performed to test the model robustness. RESULTS: Using clinical results of patients 
previously treated with a calcium-based binder, for the ITT population, the ICERs 
were $24,724/QALY, $15,053/LYS and $6,700/additional success (i.e., SP goal 
achievement), respectively. For patients who completed the randomized controlled 
trial, the ICERs of LC compared with SH were $15,285/QALY, $9,337/LYS and 
$8,265/additional success respectively. The PSAs indicated a 61.9% and 85.8% prob-
ability of LC being cost-effective at the $50,000/QALY threshold, for the ITT popula-
tion and completer populations, respectively. Sensitivity analyses support the 
robustness of the model results. CONCLUSIONS: LC is a cost-effective strategy 
compared to SH in ESRD patients previously treated with calcium-based binders.
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OBJECTIVES: The calcineurin inhibitor (CNI) based regimens have improved short-
term patient and graft survival. However, the nephrotoxicity of CNI has limited the 
long-term improvement of outcomes. Recently, sirolimus, a novel class of immunosup-
pressant, got an approval in Korea. In this report, the cost-effectiveness of sirolimus 
based regimen compared with CNI based regimens was evaluated especially in the 
lower immunological risk renal transplant patients under Korea health care system. 
METHODS: A Markov model was developed to simulate costs and outcomes of a 
renal transplant recipient for 20 years with 5% discount rate in the societal perspec-
tive. Health states were deﬁ ned as patient with graft survival, patient with graft failure, 
patient with regraft survival, patient with regraft failure and patient death. Quality 
adjusted life-years (QALYs) were taken as effectiveness parameter. Efﬁ cacy data were 
obtained from systematic review of immunosuppressive regimens in lower immuno-
logical risk renal transplant recipients. And the additional beneﬁ ts of mTOR inhibitor 
(including sirolimus), reduced nephrotoxicity and lower relative risk to the incidence 
of malignancy, were reﬂ ected in the model. Utility weights were obtained from pub-
lished literature. Costs were calculated by the Korean public institutional data and 
clinical expert opinions. Sensitivity analyses were performed on crucial parameters. 
RESULTS: Sirolimus based regimen costs KRW 130,067,696 for the 8.94QALYs for 
20 years treatment duration, whereas KRW 140,185,240 for 8.67 QALYs for tacro-
limus based regimen, and KRW 131,136,664 for 8.56 QALYs for cyclosporine based 
regimen. Sirolimus based regimen was shown to be dominant over the others, as it 
was more efﬁ cacious in QALYs and less costly. The sensitivity analysis showed that 
the results were quite robust across most parameters. CONCLUSIONS: Sirolimus 
based regimen is expected to be superior in the clinical effectiveness and cost-saving 
in lower risk renal transplant recipients compared with the most frequently prescribed 
CNI regimens in Korea.
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OBJECTIVES: Diabetic nephropathy is a serious and common complication in dia-
betic patients; however the onset and the course can be favourably inﬂ uenced by 
appropriate therapy when detected early. Current recommendations include testing of 
creatinine based estimation of glomerular ﬁ ltration rate (eGFR) and for microalbu-
minuria. Due to substantial limitations of creatinine, cystatin C (cysC) has been 
proposed as alternative marker for early detection of (chronic kidney disease) CKD. 
METHODS: We developed a Cost-Utility Model to simulate the long-term conse-
quences and disease progression for diabetic patients using serum cysC instead of 
Creatinine for monitoring of kidney function. Markov modelling techniques were used 
to estimate incidence of complications and disease progression, and Monte Carlo 
simulation accounted for uncertainty. The model includes 11 health states to describe 
the disease progression and occurrence of adverse events. Probabilities were derived 
from clinical and epidemiological studies. The cohort deﬁ nition was adapted from the 
UKPDS study. Direct medical costs from published sources were used and expressed 
in 2009 Euro from the payer’s perspective. QALYs and total costs were projected over 
a life-time horizon and discounted at 5% p.a. RESULTS: Early detection of CKD with 
cysC leads to lifetime costs of c52,950 and 14.19 QALYs (c3,732 per QALY). Detec-
tion with Creatinine amounts to c64,912 and 12.82 QALYs (c5,063 per QALY). Cost 
saving amounts to c11,962 per patient and a QALY gain of 1.37; these arise due to 
slower disease progression and reduced complications. The cumulative incidence of 
complications was estimated to be lower for cysC than Creatinine (−15%). Early 
detection with cysC leads to a decreased number of patient-years (14%-points) spent 
in ESRD, due to a later onset. Probabilistic sensitivity analyses demonstrated the 
robustness of the model. CONCLUSIONS: The economic beneﬁ t of using cysC is 
substantial, due to reduction in complications and disease progression as well as lower 
long-term costs.
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OBJECTIVES: Major controversy exists regarding the optimal treatment strategy in 
Acute Kidney Injury (AKI). The purpose of this study was to assess the incremental 
cost-effectiveness of continuous (CRRT) versus intermittent renal replacement therapy 
(IRRT) and conservative (CONS) AKI treatment in Belgium. METHODS: An area 
under the curve model was used, whereby patients are simulated using time-to-event 
data (survival analysis), combined with daily direct medical costs. Data were derived 
from the multi-centre SHARF4 study in which the three treatment modalities for AKI 
were compared. a time horizon of 2 years, starting from the admission to the hospital, 
was considered. Utility data were obtained from SF-36 assessment at 2 years and from 
literature data on in-hospital utility. RESULTS: Analyses indicated that mortality 
rates, cost and length of stay differed signiﬁ cantly between treatment mode during 
hospitalization. The mortality rate and the cost per day during the post-discharge 
follow-up period showed no signiﬁ cant difference between the treatment modes. 
Utility values, which improved gradually after admission to the hospital, revealed no 
signiﬁ cant differences between the three treatment strategies. Conservative treatment 
was associated with a 2-year cost of c34,090 and 0.49 QALYs. The CRRT was the 
most expensive therapy with a cost of c51,664 leading to 0.52 QALYs. The cost and 
QALYs associated with IRRT were c43,711 and 0.46. The ICER of CRRT versus 
IRRT was c131,604/QALY, while the ICER of CRRT versus CONS amounted to 
c651,318/QALY. Additionally the conservative treatment dominated IRRT. Sensitiv-
ity analysis—tornado diagram—conﬁ rmed the robustness of the results. CONCLU-
SIONS: This study has indicated that the most expensive treatment (CRRT) associated 
with an incremental cost of approximately c7952 generates only a minor increase in 
QALYs of 0.06 compared to IRRT. Additionally the results revealed that IRRT was 
dominated by CONS. From a health economic perspective conservative therapy seems 
to be the preferred treatment strategy.
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OBJECTIVES: A probabilistic patient-level Markov model was developed to simulate 
lifetime clinical and economic outcomes of the cinacalcet treatment in secondary 
hyperparathyroidism (SHPT) patients. We present the adaptation of this model to ﬁ ve 
European countries: Italy, Spain, Portugal, Czech Republic and Switzerland. 
METHODS: In the simulation the treatment with cinacalcet inﬂ uences the trend in 
time of individual parathyroid hormone (PTH), serum calcium (Ca) and phosphorous 
(P) levels, based on the OPTIMA study. Published correlations between these levels, 
mortality and morbidity (CV events, fractures, and parathyroidectomies) were incor-
porated as well as local epidemiologic and cost data for dialysis, drugs and events 
management. Simulation horizon was patient lifetime; standard treatment (vitamin D 
sterols and phosphate binders) and cinacalcet plus standard treatment were compared. 
The effectiveness was measured as life expectancy (LE) and quality-adjusted life 
expectancy (QALE). Health Utility Indexes derived from literature and took into 
account dialysis, CV events and fractures. RESULTS: The simulated mean LE exten-
sion was 1.20 life-years (LY) in Italy, 1.1 LY in Spain, 1.18 LY in Portugal, 1.10 LY 
in Czech Republic and 1.40 LY in Switzerland. QALE increase was 0.89, 0.82, 0.89, 
0.80 and 1.01 quality-adjusted life-years (QALY) in the same countries, respectively. 
The lifetime average cost increase, calculated not taking into account the cost for 
dialysis, was c28,161 in Italy, c23,878 in Spain, c27,932 in Portugal, CZK 836,914 
(corresponding to c32,751) in Czech Republic and CHF 48,908 (c34,630) in Switzer-
land. The incremental cost-effectiveness ratio (ICER) was c23,473/LY and c31,616/
QALY in Italy, c21,789/LY and c29,270/QALY in Spain, c23,680/LY and c31,249/
QALY in Portugal, CZK 759,600/LY (approx. c29,726/LY) and CZK 1,042,643/
QALY (approx. c40,802/QALY) in Czech Republic and CHF 34,858/LY (approx. 
c24,682/LY) and CHF 48,310/QALY (approx. c34,207/QALY) in Switzerland. CON-
CLUSIONS: Cinacalcet treatment could be considered a cost-effective treatment of 
SHPT in all the countries analyzed. Results seem more homogeneous in the three 
southern countries.
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OBJECTIVES: Pharmacological interventions that are of beneﬁ t in non-dialysis popu-
lations have thus far been disappointing in dialysis patients. Since clinical trials are 
expensive and time-consuming, adjunct strategies are needed to support decision 
